Journal: Molecular Medicine
Article Title: Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4 int FOXP3 int regulatory T-cell production in rheumatoid arthritis
doi: 10.1186/s10020-025-01372-6
Figure Lengend Snippet: UCP2 suppresses CPT2 expression by impairing oxidative signaling and protein acetylation. CD4 + CD45RO − T cells from HCs were treated with vehicle or Genipin at indicated dose on day 3 after anti-CD3/CD28 bead stimulation. A Correlation of mitochondrial membrane potential (MΦ) with UCP2 activity. MΦ was assessed by FACS. B Correlation of CPT2 expression with MΦ. CPT2 expression and MΦ were assessed by FACS. C-E CPT2 expression regulated by ROS. C ROS levels from RA patients and HCs were measured with H2DCFDA probe on day 3. D RA-derived CD4 + T cells were treated with Genipin on day 3 and ROS levels were measured after 24 h. E HC-derived CD4 + T cells were transfected with control and mCherry-UCP2 plasmids on day 3 and ROS levels were measured after 24 h. F HC-derived CD4 + T cells were treated with vehicle or TEMPO (20 μM) on day 3 for 24 h. CPT2 levels were measured by FACS. G HC-derived CD4 + T cells were treated with vehicle or NAC 20 μM on day 3 for 24 h. CPT2 levels were measured by FACS. H - I CPT2 expression after TEMPO and NAC treatment was measured by Western blotting and quantified at ( I ). J - K HC-derived CD4 + T cells were treated with vehicle, NAC 20 mM, or NAC and Genipin 25 μM on day 3 for 24 h. J CPT2 levels were measured by FACS and quantified at ( K ). L - M CPT2 protein expression after NAC 20 mM, or NAC and Genipin treatment were measured by Western blotting. N CPT2 acetylation was determined by a Co-immunoprecipitation assay with anti-CPT2 followed by immunoblotting with anti-acetylated-lysine antibody. O RA-derived CD4 + T cells were treated with Genipin and CPT2 acetylation were measured by Co-immunoprecipitation. All data were presented as the mean ± SEM. ** p < 0.01; *** p < 0.001; n.s., non-significance
Article Snippet: To sort CD4 + CD45RO − cells, Peripheral blood mononuclear cells (PBMCs) were negatively selected with CD45RO microbeads (130–046-001, Miltenyi Biotec Inc., Auburn, USA), followed by positive selection with CD4 micro-beads (130–097-048, Miltenyi Biotec Inc.) using autoMACS (130–097-048, Miltenyi Biotec Inc.).
Techniques: Expressing, Membrane, Activity Assay, Derivative Assay, Transfection, Control, Western Blot, Co-Immunoprecipitation Assay, Immunoprecipitation